Christian Bernard Brechot

This inventor holds 12 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: National Institute of Health and Medical Research, Institut Pasteur, Université Paris—sud. Active years: 1998-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christian Bernard Brechot. Retrieved from https://idiyas.com/inventor/christian-bernard-brechot

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 36(Granted Patents)

Location History:

Paris Cedex, FR (1998 - 2000)
Paris, FR (1999 - 2022)
Tampa, FL (US) (2023)

Company Filing History:

7 out of 1,853

National Institute of Health and Medical Research

Assistance Publique-Hopitaux De Paris

patents

6. 1 out of 285

National Institute for Agricultural Research

patents

7. 1 out of 111

Université Paris Diderot-Paris 7

patents

8. 1 out of 3

Universite Rene Descartes

patents

9. 1 out of 1,990

University of South Florida

patents

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11766429 - Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19 (2023-09-26),

2. 11484569 - Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria (2022-11-01),

3. 9629896 - Composition including the HIP/PAP protein or one of the derivatives thereof for treating insulin resistance (2017-04-25),

4. 9474783 - HIP/PAP protein and derivatives thereof for use in treating cancer (2016-10-25),

5. 8329661 - Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure (2012-12-11),

6. 6210962 - Nucleotide and peptide sequences of an isolate of the hepatitis C virus, diagnostic and therapeutic applications thereof (2001-04-03),

7. 6103887 - Nucleotide sequence encoding human cyclin A (2000-08-15),

8. 6020123 - Oligonucleotide sequences for the amplification of the genome of the (2000-02-01),

9. 5919454 - Nucleotide and peptide sequences of a hepatitis C virus isolate, (1999-07-06),

10. 5879904 - Nucleotide and peptide sequences of a hepatitis C virus isolate, (1999-03-09),

11. 5866139 - Nucleotide and peptide sequences of a hepatitis C virus isolate, (1999-02-02),

12. 5849508 - Process for the detection of cell proliferation by detecting human (1998-12-15),

Title: Innovations in COVID-19 Treatment by Christian Bernard Brechot

Introduction

Christian Bernard Brechot is an innovative inventor based in Tampa, FL (US). He has made significant contributions to the field of medical research, particularly in the treatment of COVID-19. His work focuses on the development of therapeutic agents that target the mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Latest Patents

Brechot holds a patent for "Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19." This patent presents a method of treating COVID-19 infection by administering nicotinic receptor antagonists and/or PPAR-γ agonists. The combination of mecamylamine, or an isomer thereof, and pioglitazone has been shown to synergistically reduce the replication of SARS-CoV-2 in virus-infected cells. Additionally, it reduces inflammatory cytokines such as IL-6, IL-β, and TNFα, which are associated with SARS-CoV-2 infection. He has 1 patent to his name.

Career Highlights

Brechot is affiliated with the University of South Florida, where he conducts his research and develops innovative solutions for pressing health issues. His work has garnered attention for its potential impact on public health, especially during the ongoing pandemic.

Collaborations

Some of his notable coworkers include Paul R. Sanberg and Shyam S. Mohapatra, who have collaborated with him on various research projects.

Conclusion

Christian Bernard Brechot's contributions to the field of COVID-19 treatment highlight the importance of innovation in addressing global health challenges. His research continues to pave the way for new therapeutic strategies against viral infections.

Profile summary based on public USPTO records.